pyrazines has been researched along with dehydroxymethylepoxyquinomicin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Utsunomya, A | 1 |
| Bonavida, B; Huerta-Yepez, S; Jazirehi, AR; Martinez-Maza, O; Martinez-Paniagua, M; Umezawa, K; Vega, MI | 1 |
1 review(s) available for pyrazines and dehydroxymethylepoxyquinomicin
| Article | Year |
|---|---|
[Clinical and hematological characteristics of adult T-cell leukemia/lymphoma].
Topics: Benzamides; Boronic Acids; Bortezomib; Carrier State; Cyclohexanones; HIV Protease Inhibitors; Human T-lymphotropic virus 1; Humans; Infectious Disease Transmission, Vertical; Leukemia-Lymphoma, Adult T-Cell; NF-kappa B; Protease Inhibitors; Pyrazines; Ritonavir; Stem Cell Transplantation; Transplantation, Homologous | 2006 |
1 other study(ies) available for pyrazines and dehydroxymethylepoxyquinomicin
| Article | Year |
|---|---|
The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclohexanones; Drug Resistance, Neoplasm; Humans; Lymphoma, AIDS-Related; Lymphoma, B-Cell; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Rituximab | 2008 |